Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

Primary and Secondary Endpoints Do Not Achieve Statistical Significance

Company Affirms Plans to File NGX-4010 NDA in 2008

Schedules Investor Conference Call at 5:00 p.m. EST

SAN MATEO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced preliminary top-line results from study C119, its second Phase 3 clinical trial of NGX-4010, the Company's dermal patch drug candidate, in patients with HIV-distal sensory polyneuropathy (HIV-DSP). The prespecified analysis of the primary endpoint, comparing all patients treated with NGX-4010 compared to all patients treated with the control patch, did not meet statistical significance (p=0.1), with the overall NGX-4010 treatment group achieving a 29.5% reduction in pain from baseline over weeks 2 to 12 compared to a 24.6% reduction for the control group. The results were confounded by a much higher than anticipated control group response overall and, in particular, in the 60-minute control arm.

Dr. Jeffrey Tobias, Chief Medical Officer, commented, "We observed responses in the NGX-4010 treatment arms consistent with what we have seen in multiple previous studies. However, the response in the 60-minute control group was greater than anticipated. We are encouraged that the safety profile of this study supports the lack of any observed major safety issues associated with NGX-4010 and that treatment with NGX-4010 was well tolerated. Since these results are preliminary, we have more analysis to carry out on this data. However, our initial evaluation of the data suggests that the NGX-4010 treatment arms behaved similarly to our oth
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...   LabStyle Innovations Corp . (OTCQB:DRIO), developer of ... appointment of Professor Richard B. Stone ... Directors. Prof. Stone brings over forty-five ... as an entrepreneur, venture capitalist public, company officer ... He currently serves on the board of directors ...
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Reportlinker.com announces that a new market research ... Advanced Drug Delivery Markets (Liposomes, Polymers and ... Drug delivery is evolving at a ... discovered frequently. Advanced drug delivery deals with developing ...
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: France Pharmaceutical Market Overview ... http://www.reportlinker.com/p0360215/France-Pharmaceutical-Market-Overview-–--Austerity-measures-will-impact-pharmaceutical-market-growth.html ... pharma market in France was valued at $38.8bn ...
Cached Medicine Technology:Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth 2
(Date:7/11/2014)... 2014 Alliance for Cancer Gene ... dedicated exclusively to cell and gene therapies for ... joined the organization as Senior Development Officer. , ... experience securing gifts and addressing influential donors. Prior ... Director for NewYork Presbyterian Hospital/Columbia University Medical Center, ...
(Date:7/11/2014)... As reported by the New York Times ... number of severe adverse events such as renal failure, ... from the highly-promoted and costly immune-system drug, Acthar, have ... , a regulatory filing revealed that the total number ... 14% of prescriptions, up from 9.1% in 2011. Specifically, ...
(Date:7/11/2014)... surgery to repair damage to the anterior cruciate ligament (ACL) ... -- could increase a young athlete,s risk for further injuries, ... patients, aged 8 to 16, who had ACL reconstruction surgery. ... after their injury, 37 had surgery six to 12 weeks ... after their injury. The youngsters who had surgery later ...
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
(Date:7/11/2014)... unravel mechanisms that guide function and differentiation of blood ... including our immune system. The study of human blood ... found in the bone marrow in specialized "niches" that ... group of scientists from Dresden led by stem cell ... to generate a mouse model that supports the transplantation ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2
... and ISMANING, Germany, Oct. 17 /PRNewswire-FirstCall/,-- XIRING ... security solutions,for remote transactions, and SCM Microsystems ... of solutions that open the Digital,World, today ... eHealth,smart card terminals for the new generation ...
... today filed an amicus brief on behalf of ten ... RU-486., AUL President Dr. Charmaine Yoest stated, "RU-486 ... women,s lives. We must put a stop to,abortionists, dangerous, ... in the right direction, and as we argue in ...
... into any grocery store,and there,s likely to be ... struggle with mindless eating have already begun to ... people find that Halloween spurs,a particularly tough time ... coming, it,only becomes more challenging. Dieters, mindless eaters, ...
... SPRINGFIELD, Mass., Oct. 16 With a combination ... become its hallmark, Massachusetts Mutual Life Insurance Company,(MassMutual) ... to the cause,of Breast Cancer Awareness Month., ... contribute tens of thousands,of dollars to cancer research, ...
... Alert Urges HR/Leadership Development to Implement Post-Crash Development Programs with ... ... Gainesville, FL (PRWEB) October 16, 2008 -- ... and how human resources and leadership development can quickly ...
... researcher, clinical nutritionist and women,s health practitioner, has ... Revitalizer, designed to bring back thicker, fuller hair ... Nails Revitalizer is available exclusively through Doctors, Preferred, ... one of the largest North American direct-mail supplement ...
Cached Medicine News:Health News:XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market 2Health News:XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market 3Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2Health News:A Mindful Chocolate Meditation 2Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 2Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 3Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 4Health News:Perth Leadership Institute Issues Alert on the Post-Crash Environment Facing HR/Leadership Development 2Health News:Perth Leadership Institute Issues Alert on the Post-Crash Environment Facing HR/Leadership Development 3Health News:Dr. Lark Creates Nutritional Supplement to Restore Thick Hair and Strong Nails 2Health News:Dr. Lark Creates Nutritional Supplement to Restore Thick Hair and Strong Nails 3
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
Medicine Products: